Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

Cytokine storm seems to be a common feature of severe COVID-19 pathology. Here, the authors show a reduced rate of SARS-CoV2 positivity in a large population of patients with immune-mediated inflammatory diseases if they are already being treated with cytokine or JAK inhibitors, indicating these tre...

Full description

Bibliographic Details
Main Authors: David Simon, Koray Tascilar, Gerhard Krönke, Arnd Kleyer, Mario M. Zaiss, Franz Heppt, Christine Meder, Raja Atreya, Entcho Klenske, Peter Dietrich, Abdullah Abdullah, Thorsten Kliem, Giulia Corte, Harriet Morf, Moritz Leppkes, Andreas E. Kremer, Andreas Ramming, Milena Pachowsky, Florian Schuch, Monika Ronneberger, Stefan Kleinert, Clara Maier, Axel J. Hueber, Karin Manger, Bernhard Manger, Carola Berking, Matthias Tenbusch, Klaus Überla, Michael Sticherling, Markus F. Neurath, Georg Schett
Format: Article
Language:English
Published: Nature Publishing Group 2020-07-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-020-17703-6

Internet

https://doi.org/10.1038/s41467-020-17703-6

Similar Items